GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TOWA Pharmaceutical Co Ltd (TSE:4553) » Definitions » Debt-to-EBITDA

TOWA Pharmaceutical Co (TSE:4553) Debt-to-EBITDA : 6.85 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is TOWA Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

TOWA Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円12,563 Mil. TOWA Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円183,611 Mil. TOWA Pharmaceutical Co's annualized EBITDA for the quarter that ended in Dec. 2023 was 円28,640 Mil. TOWA Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 6.85.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for TOWA Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4553' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.07   Med: 3.05   Max: 10.58
Current: 10.58

During the past 13 years, the highest Debt-to-EBITDA Ratio of TOWA Pharmaceutical Co was 10.58. The lowest was 1.07. And the median was 3.05.

TSE:4553's Debt-to-EBITDA is ranked worse than
92.54% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs TSE:4553: 10.58

TOWA Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for TOWA Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOWA Pharmaceutical Co Debt-to-EBITDA Chart

TOWA Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 2.74 2.81 4.21 6.55

TOWA Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -127.91 69.98 6.17 13.28 6.85

Competitive Comparison of TOWA Pharmaceutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOWA Pharmaceutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where TOWA Pharmaceutical Co's Debt-to-EBITDA falls into.



TOWA Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

TOWA Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11204 + 150314) / 24649
=6.55

TOWA Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12563 + 183611) / 28640
=6.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


TOWA Pharmaceutical Co  (TSE:4553) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


TOWA Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of TOWA Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


TOWA Pharmaceutical Co (TSE:4553) Business Description

Traded in Other Exchanges
N/A
Address
2-11, Shinbashi-cho, Kadoma, Osaka, JPN, 571-8580
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.

TOWA Pharmaceutical Co (TSE:4553) Headlines

No Headlines